Leprosy Patients in Nigeria Face Year-Long Wait for Treatment as Bureaucratic Delays Stall Drug Distribution

For over a year, thousands of leprosy patients across Nigeria have been left without life-saving multi-drug therapy (MDT), a situation experts warn has worsened their conditions and increased the risk of transmission. Among the 3,000 affected are 800 children, many of whom have seen their symptoms deteriorate due to the prolonged wait. At the heart of the crisis is a regulatory bottleneck. The World Health Organization (WHO), which supplies MDT globally, delivered the drugs, but Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) required additional certifications before allowing distribution. The result? A backlog of suffering and a growing health emergency. The delay is not just a bureaucratic misstep; it is a crisis with far-reaching implications. Health workers have reported worsening cases, with some patients developing severe disabilities due to the lack of timely intervention. Leprosy, a disease once thought to be on the decline, continues to affect thousands in Nigeria, making swift treatment essential in preventing irreversible damage and further community spread.

While the shipment of MDT finally arrived in Nigeria on March 9, the question remains: How quickly will it reach those in need? Past cases suggest caution. In 2023, a similar delay, though shorter, left hundreds of patients untreated for months. The frequency of such disruptions is raising concerns about systemic failures in Nigeria’s public health response to neglected tropical diseases. The worst-hit areas include parts of northern Nigeria, with Kano and Kebbi states recording some of the highest cases. Local officials, including the chairman of the Kebbi State Health Committee, Hon. Yusuf Bawa, have called for an urgent review of Nigeria’s drug clearance policies to prevent future crises. “Delays of this nature should not happen when lives are at stake,” Bawa said.

Public health experts argue that Nigeria must strengthen coordination between its regulatory agencies and international health bodies. Without a clear, streamlined process, delays like this will continue to put lives at risk. The WHO has reiterated its commitment to providing treatment, but the responsibility for timely distribution lies with Nigerian authorities. For the patients still waiting, the arrival of the drugs is only part of the solution. The real test will be how quickly they get into the hands of those who need them most.